申请人:Farmitalia Carlo Erba S.r.l.
公开号:US05436235A1
公开(公告)日:1995-07-25
The present invention relates to 3-aryl-oxirane derivatives of the formula ##STR1## wherein Ar is 4'-quinoline or 5'-quinoline; each of R and R.sub.1 independently is hydrogen or C.sub.1 -C.sub.6 alkoxy; one of X and Y is hydrogen, cyano, --COOR.sub.2 or --CONR.sub.3 R.sub.4, and the other of X and Y is cyano, --COOR.sub.2 or --CONR.sub.3 R.sub.4, wherein R.sub.2 is C.sub.1 -C.sub.6 alkyl and each of R.sub.3 and R.sub.4 independently is hydrogen or C.sub.1 -C.sub.6 alkyl, and pharmaceutically acceptable salts thereof, which are useful in therapy as tyrosine kinase inhibitors, in particular as anti-proliferative agents, typically as anti-cancer agents, in the treatment of psoriasis and in inhibiting the development of atheromatous plaque.
本发明涉及公式##STR1##的3-芳基环氧乙烷衍生物,其中Ar是4'-喹啉或5'-喹啉;R和R.sub.1中的每一个独立地是氢或C.sub.1 -C.sub.6烷氧基;X和Y中的一个是氢、氰基、--COOR.sub.2或--CONR.sub.3R.sub.4,另一个是氰基、--COOR.sub.2或--CONR.sub.3R.sub.4,其中R.sub.2是C.sub.1 -C.sub.6烷基,R.sub.3和R.sub.4中的每一个独立地是氢或C.sub.1 -C.sub.6烷基,以及其在治疗中作为酪氨酸激酶抑制剂的药学上可接受的盐,特别是作为抗增殖剂,通常作为抗癌剂,在治疗银屑病和抑制动脉粥样硬化斑块发展方面具有用途。